ArticleBMC oral health2026
Soy-isoflavone to remedy induced or post-gamma-irradiation periodontitis in rat model.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy remains a cornerstone in tumour management; however, it can lead to deleterious effects on alveolar bone, including hypovascularity, endarteritis, and osteoradionecrosis. Periodontitis is a chronic inflammatory disease characterized by progressive alveolar bone loss and eventual tooth loss. Isoflavones, plant-derived phytoestrogens, have been recognized for their bone-protective and anti-osteoporotic properties. This study aimed to investigate the therapeutic efficacy of two different concentrations of isoflavones in mitigating gamma radiation- and ligature-induced periodontitis in rats' mandibles.
methodsForty-eight male albino rats were divided into six groups: gamma radiation-induced periodontitis (R), ligature-induced periodontitis (P), gamma radiation-induced periodontitis treated with 20 mg/kg isoflavones (R20), ligature-induced periodontitis treated with isoflavones at 20 mg/kg (P20), gamma radiation-induced periodontitis treated with 50 mg/kg isoflavones (R50), and ligature-induced periodontitis treated with isoflavones at 50 mg/kg (P50). Following euthanasia, mandibles were divided into two halves for radiographic bone density and histopathological assessments.
resultsThe lowest bone density values were recorded in the R group, while the P50 group exhibited the highest bone density. A trend toward improvement in bone mineralization with increasing dose of isoflavones. Histologically, the R group showed hypovascular Haversian canals, osteocytes with eccentric nuclei, and enlarged lacunae. R20 group demonstrated partially restored vascularity, Haversian canals containing blood vessels, and osteocytes showing wide and narrow lacunae. R50 group exhibited marked improved histoarchitecture, narrow Haversian canals containing red blood cell-filled vessels, and well-organized bone matrix. In the P group, marked alveolar bone and periodontal ligament loss were evident, with osteocytes exhibiting enlarged lacunae. Isoflavone at 20 mg/kg (P20) resulted in partial regeneration of periodontal fibers and normalization of lacunar morphology, whereas a 50 mg/kg dose (P50) led to pronounced periodontal regeneration, narrow Haversian canals containing vascular structures, and distinct Volkmann's, Zuckerkandl, and Hirschfeld canals.
conclusionIsoflavones, particularly at a concentration of 50 mg/kg body weight, effectively preserved bone microarchitecture, enhanced vascularization, and promoted periodontal tissue regeneration. These findings suggest that isoflavone may serve as a promising adjunctive therapeutic agent for mitigating radiation-associated and inflammatory alveolar bone loss.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.